secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-05-13T12:00:44+00:00
Accession:  0001193125-26-220638
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026
---------------------------------------------------------------------------

- Net loss $39.3M vs $28.1M YoY; R&D expenses $33.5M (+34%) driven by dabogratinib trials.
- Cash, equivalents & marketable securities $383.5M; runway into 2H 2028.
- First patient dosed in LG-UTUC trial SURF303 (pivotal); initial results expected 2027.
- Initial SURF302 data (IR NMIBC) due August 2026; BEACH301 safety sentinel data Q4 2026.
- Appointed Habib Dable to Board; raised $147.9M net via ATM in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/0001193125-26-220638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-220638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer